Abstract
Human parvovirus B19 is a frequent contaminant of blood and plasma-derived medicinal products and transmission of this virus has been shown to occur through the administration of contaminated products. Inactivation of the virus has proved difficult and as a consequence, manufacturers of blood products have implemented screening measures to reduce the load of parvovirus B19 in manufacturing plasma pools by the use of nucleic acid amplification techniques (NAT). We present data comparing the performance of two commercially available kits for the detection and quantitation of parvovirus B19 DNA using the LightCycler, and determine their applicability for the detection of recently discovered variants of the virus. Parvovirus B19 DNA was readily quantified using both commercial assays. However, one kit failed to detect any of the variant viruses. The second kit detected the variant viruses although there was a marked difference in the sensitivity of detection of the different virus genotypes. To improve the detection of these variant viruses a novel assay has been developed and data are presented to show its use for screening pooled plasma for the presence of parvovirus B19 DNA and the variants identified recently.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.